Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR9237] to ERCC8
- Suitable for: IP, WB
- Knockout validated
- Reacts with: Human
Product nameAnti-ERCC8 antibody [EPR9237]
See all ERCC8 primary antibodies
DescriptionRabbit monoclonal [EPR9237] to ERCC8
Tested applicationsSuitable for: IP, WBmore details
Unsuitable for: Flow Cyt,ICC/IF or IHC-P
Species reactivityReacts with: Human
Synthetic peptide corresponding to residues in Human ERCC8 (UniProt ID: Q13216)
- HeLa, Molt-4, 293T, and HepG2 whole cell lysate (ab7900).
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab137033 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||1/10 - 1/100.|
|WB||1/1000 - 1/10000. Predicted molecular weight: 44 kDa.|
FunctionSubstrate-recognition component of the CSA complex, a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex, involved in transcription-coupled nucleotide excision repair. The CSA complex (DCX(ERCC8) complex) promotes the ubiquitination and subsequent proteasomal degradation of ERCC6 in a UV-dependent manner; ERCC6 degradation is essential for the recovery of RNA synthesis after transcription-coupled repair. It is required for the recruitement of XAB2, HMGN1 and TCEA1/TFIIS to a transcription-coupled repair complex which removes RNA polymerase II-blocking lesions from the transcribed strand of active genes.
PathwayProtein modification; protein ubiquitination.
Involvement in diseaseDefects in ERCC8 are the cause of Cockayne syndrome type A (CSA) [MIM:216400]. Cockayne syndrome is a rare disorder characterized by cutaneous sensitivity to sunlight, abnormal and slow growth, cachectic dwarfism, progeroid appearance, progressive pigmentary retinopathy and sensorineural deafness. There is delayed neural development and severe progressive neurologic degeneration resulting in mental retardation. Two clinical forms are recognized: in the classical form or Cockayne syndrome type 1, the symptoms are progressive and typically become apparent within the first few years or life; the less common Cockayne syndrome type 2 is characterized by more severe symptoms that manifest prenatally. Cockayne syndrome shows some overlap with certain forms of xeroderma pigmentosum. Unlike xeroderma pigmentosum, patients with Cockayne syndrome do not manifest increased freckling and other pigmentation abnormalities in the skin and have no significant increase in skin cancer.
Sequence similaritiesContains 5 WD repeats.
- Information by UniProt
- CKN1 antibody
- Cockayne syndrome type A antibody
- Cockayne syndrome WD repeat protein CSA antibody
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: ERCC8 knockout HAP1 cell lysate (20 µg)
Lane 3: HeLa cell lysate (20 µg)
Lane 4: Molt-4 cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab137033 observed at 44 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab137033 was shown to recognize ERCC8 when ERCC8 knockout samples were used, along with additional cross-reactive bands. Wild-type and ERCC8 knockout samples were subjected to SDS-PAGE. ab137033 and ab8245 (loading control to GAPDH) were diluted 1/1000 and 1/2000 respectively, and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.
All lanes : Anti-ERCC8 antibody [EPR9237] (ab137033) at 1/1000 dilution
Lane 1 : Hela cell lysate
Lane 2 : Molt 4 cell lysate
Lane 3 : 293T cell lysate
Lane 4 : HepG2 cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP conjugated Goat anti Rabbit IgG at 1/2000 dilution
Predicted band size: 44 kDa
ab137033 has been referenced in 5 publications.
- Wienholz F et al. FACT subunit Spt16 controls UVSSA recruitment to lesion-stalled RNA Pol II and stimulates TC-NER. Nucleic Acids Res N/A:N/A (2019). PubMed: 30715484
- Crochemore C et al. CSB promoter downregulation via histone H3 hypoacetylation is an early determinant of replicative senescence. Nat Commun 10:5576 (2019). PubMed: 31811121
- Slyskova J et al. Base and nucleotide excision repair facilitate resolution of platinum drugs-induced transcription blockage. Nucleic Acids Res 46:9537-9549 (2018). PubMed: 30137419
- Pines A et al. TRiC controls transcription resumption after UV damage by regulating Cockayne syndrome protein A. Nat Commun 9:1040 (2018). WB . PubMed: 29531219
- Iyama T & Wilson DM Elements That Regulate the DNA Damage Response of Proteins Defective in Cockayne Syndrome. J Mol Biol 428:62-78 (2016). PubMed: 26616585